Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

News

News
Anthos Therapeutics Unveils Additional Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating that the Factor XI Inhibitor Abelacimab was Associated with Remarkably Low Levels of Periprocedural Bleeding in Patients with Atrial Fibrillation
09/03/2024
Anthos Therapeutics Press Release  CAMBRIDGE, MASS., September 2, 2024 – Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the treatment of...
Anthos Therapeutics Press Release  CAMBRIDGE, MASS., September 2, 2024 – Anthos Therapeutics, Inc., a transformative, clinical-stage biopharmaceutical company developing innovative therapeutic options for the treatment of...
Anthos Therapeutics Press...
09/03/2024
EP Lab Digest

Advertisement

News
Wearable Heart Monitor Increases Diagnosis of Irregular Heart Rhythm
09/03/2024
A large study increased diagnoses of atrial fibrillation, but did not have enough participants to demonstrate stroke reduction
A large study increased diagnoses of atrial fibrillation, but did not have enough participants to demonstrate stroke reduction
A large study increased...
09/03/2024
EP Lab Digest
News
Atrial Fibrillation Guidelines Focus on Shared and Equal Care, Patient Empowerment, Comorbidities, Evidence-based Management, and Dynamic Re-evaluation
08/30/2024
AF prevalence expected to double in coming decades – new ESC Guidelines focus on tackling comorbidities, education for patients and families, and shared decision making
AF prevalence expected to double in coming decades – new ESC Guidelines focus on tackling comorbidities, education for patients and families, and shared decision making
AF prevalence expected to double...
08/30/2024
EP Lab Digest
News
ESC Congress 2024: Bayer to Present Phase III KERENDIA® (finerenone) Data
08/30/2024
Bayer Press Release WHIPPANY, N.J -- Bayer will present late-breaking Phase III data from the FINEARTS-HF trial investigating KERENDIA® (finerenone) in patients with heart failure (HF) and LVEF ≥40% (left ventricular ejection...
Bayer Press Release WHIPPANY, N.J -- Bayer will present late-breaking Phase III data from the FINEARTS-HF trial investigating KERENDIA® (finerenone) in patients with heart failure (HF) and LVEF ≥40% (left ventricular ejection...
Bayer Press Release WHIPPANY,...
08/30/2024
EP Lab Digest

Advertisement

News
Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress
08/30/2024
Alnylam Pharmaceuticals Press Release CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an...
Alnylam Pharmaceuticals Press Release CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an...
Alnylam Pharmaceuticals Press...
08/30/2024
EP Lab Digest
News
GE HealthCare Showcases Latest AI-Enhanced Cardiology Solutions to Enable Real-Time Cardiac Imaging and Assessments at the Point of Care at ESC 2024
08/30/2024
CE mark of these next-generation cardiac imaging systems will further enable connected care along the cardiology patient journey and provide clinicians with the tools to deliver more efficient and timely care
CE mark of these next-generation cardiac imaging systems will further enable connected care along the cardiology patient journey and provide clinicians with the tools to deliver more efficient and timely care
CE mark of these next-generation...
08/30/2024
EP Lab Digest
GUIDELINES
New ESC Hypertension Guidelines Recommend Intensified BP Targets and Introduce a Novel Elevated Blood Pressure Category
08/30/2024
Whereas prior guidelines generally recommended patients be treated to a BP
Whereas prior guidelines generally recommended patients be treated to a BP
Whereas prior guidelines...
08/30/2024
Cath Lab Digest

Advertisement

Sleep and CVD
Catching Up on Sleep on Weekends May Lower Heart Disease Risk By Up to 20%
08/29/2024
The UK Biobank study of more than 90,000 individuals showed that those who had the most catch-up sleep on weekends had a 20% lower risk of developing heart disease than those with the least.
The UK Biobank study of more than 90,000 individuals showed that those who had the most catch-up sleep on weekends had a 20% lower risk of developing heart disease than those with the least.
The UK Biobank study of more...
08/29/2024
Cath Lab Digest
News
iRhythm Technologies Expands Global Reach with the Launch of Zio® Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain
08/29/2024
iRhythm Technologies Press Release Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization...
iRhythm Technologies Press Release Zio long-term continuous monitoring (LTCM) service consists of a prescription only patch ECG monitoring device (Zio® monitor) worn for up to 14 days, the ZEUS (Zio ECG Utilization...
iRhythm Technologies Press...
08/29/2024
EP Lab Digest
ESC2024
Cardiovascular Disease Disproportionately Affects Middle-Income Countries
08/28/2024
Professor Adam Timmis pointed to new data suggesting that treatment factors may contribute to inequalities in CVD mortality, with middle-income countries substantially under-resourced in terms of specialist staffing, and diagnostic and...
Professor Adam Timmis pointed to new data suggesting that treatment factors may contribute to inequalities in CVD mortality, with middle-income countries substantially under-resourced in terms of specialist staffing, and diagnostic and...
Professor Adam Timmis pointed to...
08/28/2024
Cath Lab Digest

Advertisement

Advertisement

EPLD November 2024 cover

Current Issue

November 2024
Volume 24
Issue 11
Current Issue
Issue Archive

Advertisement

Advertisement

Stay in the know.

EP Lab Digest Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use